AR061653A1 - Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) - Google Patents
Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3)Info
- Publication number
- AR061653A1 AR061653A1 ARP070102832A ARP070102832A AR061653A1 AR 061653 A1 AR061653 A1 AR 061653A1 AR P070102832 A ARP070102832 A AR P070102832A AR P070102832 A ARP070102832 A AR P070102832A AR 061653 A1 AR061653 A1 AR 061653A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- optionally substituted
- carbocyclyl
- carbamoyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000001267 GSK3 Human genes 0.000 title 1
- 108060006662 GSK3 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 title 1
- -1 nitro, cyano, hydroxy, amino, sulfamoyl Chemical group 0.000 abstract 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000000623 heterocyclic group Chemical group 0.000 abstract 13
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 9
- 229910052757 nitrogen Inorganic materials 0.000 abstract 8
- 125000001475 halogen functional group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 abstract 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente también se refiere a formulaciones farmacéuticas que contienen dicho compuesto y al uso de dicho compuesto en terapia, para trastornos cognitivos, diabetes, osteoporosis. La presente se refiere además a un proceso para la preparacion del compuesto de formula (1). Reivindicacion 1: Un compuesto de formula (1), donde A es heterociclilo o carbociclilo; donde dicho heterociclilo o carbociclilo está opcionalmente sustituido en carbono con uno o más R1 y donde si dicho heterociclilo contiene una porcion -NH-, ese nitrogeno puede estar opcionalmente sustituido con un grupo -R5-R7, con la salvedad de que dicho carbociclilo no es fenilo; R1 se selecciona entre halo, nitro, ciano, hidroxi, amino, sulfamoilo, carbamoilo, alquilo C1- 3, un carbociclilo, un heterociclilo y un grupo -R6-R7, donde dicho alquilo C1-3 está opcionalmente sustituido con uno o más halo y donde dicho carbociclilo o heterociclilo opcionalmente forma un sistema anular conjugado junto con A; R2 se selecciona entre halo, nitro, trifluorometilo, trifluorometoxi y ciano; R3 se seleccione entre metilo, alquilo C6, alquenilo C6, alquinilo C6, un carbociclilo no aromático de 6 miembros y un heterociclilo no aromático de 6 miembros, donde dicho alquilo C6, alquenilo C6, alquinilo C6, carbociclilo o heterociclilo está opcionalmente sustituido con uno o más halo, cieno, trifluorometoxi, haloalquilo C1-3 o alquilo C1-3; R4 se selecciona entre hidrogeno, alquilo C1-3, ciano y haloalquilo C1-3, donde dicho alquilo C1-3 o haloalquilo C1-3 está opcionalmente sustituido con uno o más OR8; donde R8 se selecciona independientemente entre hidrogeno, alquilo C1-6 o haloalquilo C1-6; R5 se selecciona entre -C(O)N(R9)-, -S(O)z-, -SO2N(R10)-, -SO2O- , -C(O)-, -C(O)O y (-CH2-)m; donde R9 y R10 se seleccionan independientemente entre hidrogeno o alquilo C1-6 y donde dicho alquilo C1-6 está opcionalmente sustituido con uno o más R19; y donde m es 0, 1, 2 o 3 y donde z es 1 o 2; R6 se selecciona entre -O-, -N(R11)C(O)-, -C(O)N(R12)-, -S(O)r-, -SO2N(R13)-, -N(R14)SO2-, -(CH2)pN(R15)-, -OSO2-, -C(O)-, -C(O)O-, -N(R16)C(O)O-, -N(R17)C(O)N(R18)- y (-CH2-)n; donde R11, R12, R13, R14, R15, R16, R17 y R18 se seleccionan independientemente entre hidrogeno o alquilo C1-6 y donde dicho alquilo C1-6 está opcionalmente sustituido con uno o más R19; y donde n es 0, 1, 2 o 3 y donde p es 0, 1, 2 o 3 y donde r es 0, 1 o 2; R7 se selecciona entre hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -alquil C1-4carbociclilo, -alquil C1-4heterociclilo, carbociclilo y heterociclilo; donde R7 puede estar opcionalmente sustituido en carbono con uno o más R20; y donde si dicho heterociclilo contiene una porcion -NH-, ese nitrogeno puede estar opcionalmente sustituido con un grupo seleccionado entre R21; R19 y R20 se seleccionan independientemente entre halo, nitro, ciano, hidroxi, amino, carboxi, carbamoilo, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxi C1- 6-alcoxi C1-6, alcanoílo C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N(alquil C1-6)2carbamoílo, alquil C1-6S(O)a, alcoxi C1-6carbonilo, N(alquil C1-6)sulfamoilo, N,N-(alquil C1-6)2sulfamollo, alquil C1-6sulfonilamino, carbociclilo, heterociclilo, carbociclilalquil C1-6-R22-, heterociclilalquil C1-6-R23-, carbociclil-R24- y heterociclil-R25-; donde a es 0, 1 o 2; y donde R19 y R20 independientemente uno del otro, está opcionalmente sustituido en carbono con uno o más R26; y donde si dicho heterociclilo contiene una porcion -NH-, ese nitrogeno está opcionalmente sustituido con un grupo seleccionado entre R27; R22, R23, R24 y R25 se seleccionan independientemente entre -O-, - N(R28)-, -C(O)-, -N(R29)C(O)-, -C(O)N(R30)-, -S(O)s-, -SO2N(R31)- y -N(R32)SO2-; donde R28, R29, R30, R31 y R32 se seleccionan independientemente entre hidrogeno o alquilo C1-6 y s es 0, 1 o 2; R21 y R27 se seleccionan independientemente entre alquilo C1-6, alcanoílo C1-6, alquil C1-6sulfonilo, alcoxi C1-6carbonilo, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, carbociclilo, heterociclilo, -alquil C1-6carbociclilo, -alquil C1-6heterociclilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; donde R21 y R27 independientemente uno del otro, están opcionalmente sustituido en carbono con uno o más R33; y R26 y R33 se seleccionan independientemente entre halo, nitro, ciano, -alquil C1-3hidroxi, -alquil C1-3metoxi, -alquil C1-3etoxi, -alquil C1-3isopropoxi, hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, carbamoilo, mercapto, sulfamoilo, metilo, etilo, ciclopropilo, ciclobutilo, metoxi, etoxi, acetilo, acetoxi, metilamino, etilamino, dimetilamino, dietilamino, N-metil-N-etilamino, acetilamino, N-metilcarbamoilo, N-etilcarbamoilo, N,N-dimetilcarbamoilo, N,N-dietilcarbamoilo, N-metil-N-etilcarbamoilo, metiltio, etiltio, metilsulfinilo, etilsulfinilo, mesilo, etilsulfonilo, metoxicarbonilo, etoxicarbonilo, N-metilsulfamoilo, N-etilsulfamoilo, N,N-dimetilsulfamoilo, N,N-dietilsulfamoilo, N-metil-N-etilsulfamoilo, carbociclo y heterociclo; donde dicho carbociclo o heterociclo está opcionalmente sustituido con halo, metilo, trifluorometilo, ciano o etilo; como una base libre o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81675506P | 2006-06-27 | 2006-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061653A1 true AR061653A1 (es) | 2008-09-10 |
Family
ID=38846128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102832A AR061653A1 (es) | 2006-06-27 | 2007-06-26 | Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20080188503A1 (es) |
| EP (1) | EP2046783A4 (es) |
| JP (1) | JP2009542639A (es) |
| KR (1) | KR20090024295A (es) |
| CN (1) | CN101511824A (es) |
| AR (1) | AR061653A1 (es) |
| AU (1) | AU2007265732A1 (es) |
| BR (1) | BRPI0713578A2 (es) |
| CA (1) | CA2655444A1 (es) |
| CL (1) | CL2007001882A1 (es) |
| EC (1) | ECSP088974A (es) |
| IL (1) | IL195665A0 (es) |
| MX (1) | MX2008015721A (es) |
| NO (1) | NO20090328L (es) |
| RU (1) | RU2008148903A (es) |
| TW (1) | TW200815417A (es) |
| UY (1) | UY30438A1 (es) |
| WO (1) | WO2008002245A2 (es) |
| ZA (1) | ZA200810577B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2623374A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN102459252A (zh) | 2009-04-15 | 2012-05-16 | 阿斯利康(瑞典)有限公司 | 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20170209488A1 (en) | 2014-07-17 | 2017-07-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for treating neuromuscular junction-related diseases |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| KR102206111B1 (ko) | 2019-04-01 | 2021-01-22 | 박광호 | 목욕탕용 담수 및 해수 가열시스템 |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| US20250009745A1 (en) * | 2021-02-05 | 2025-01-09 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Cdk inhibitor |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| EP1554269A1 (en) * | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| JP2007500178A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| AU2004285745A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| WO2006064251A1 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
-
2007
- 2007-06-21 TW TW096122335A patent/TW200815417A/zh unknown
- 2007-06-26 CL CL200701882A patent/CL2007001882A1/es unknown
- 2007-06-26 CN CNA2007800320192A patent/CN101511824A/zh active Pending
- 2007-06-26 KR KR1020097001643A patent/KR20090024295A/ko not_active Withdrawn
- 2007-06-26 CA CA002655444A patent/CA2655444A1/en not_active Abandoned
- 2007-06-26 WO PCT/SE2007/000621 patent/WO2008002245A2/en not_active Ceased
- 2007-06-26 AR ARP070102832A patent/AR061653A1/es not_active Application Discontinuation
- 2007-06-26 MX MX2008015721A patent/MX2008015721A/es not_active Application Discontinuation
- 2007-06-26 JP JP2009518045A patent/JP2009542639A/ja active Pending
- 2007-06-26 EP EP07748282A patent/EP2046783A4/en not_active Withdrawn
- 2007-06-26 BR BRPI0713578-5A patent/BRPI0713578A2/pt not_active IP Right Cessation
- 2007-06-26 UY UY30438A patent/UY30438A1/es unknown
- 2007-06-26 AU AU2007265732A patent/AU2007265732A1/en not_active Abandoned
- 2007-06-26 RU RU2008148903/04A patent/RU2008148903A/ru not_active Application Discontinuation
- 2007-06-27 US US11/769,113 patent/US20080188503A1/en not_active Abandoned
-
2008
- 2008-12-02 IL IL195665A patent/IL195665A0/en unknown
- 2008-12-12 EC EC2008008974A patent/ECSP088974A/es unknown
- 2008-12-12 ZA ZA200810577A patent/ZA200810577B/xx unknown
-
2009
- 2009-01-21 NO NO20090328A patent/NO20090328L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101511824A (zh) | 2009-08-19 |
| US20080188503A1 (en) | 2008-08-07 |
| TW200815417A (en) | 2008-04-01 |
| IL195665A0 (en) | 2009-09-01 |
| AU2007265732A1 (en) | 2008-01-03 |
| WO2008002245A2 (en) | 2008-01-03 |
| KR20090024295A (ko) | 2009-03-06 |
| NO20090328L (no) | 2009-01-26 |
| ZA200810577B (en) | 2009-08-26 |
| UY30438A1 (es) | 2008-01-31 |
| BRPI0713578A2 (pt) | 2012-10-23 |
| ECSP088974A (es) | 2009-01-30 |
| CL2007001882A1 (es) | 2008-02-08 |
| WO2008002245A3 (en) | 2008-02-14 |
| CA2655444A1 (en) | 2008-01-03 |
| MX2008015721A (es) | 2009-01-08 |
| JP2009542639A (ja) | 2009-12-03 |
| WO2008002245A8 (en) | 2008-10-09 |
| EP2046783A4 (en) | 2010-08-04 |
| EP2046783A2 (en) | 2009-04-15 |
| RU2008148903A (ru) | 2010-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061653A1 (es) | Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) | |
| AR064208A1 (es) | Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas. | |
| AR055249A1 (es) | Derivados de quinazolinas, procesos de obtencion y composiciones farmaceuticas | |
| AR054183A1 (es) | Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. | |
| AR070493A1 (es) | Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas. | |
| AR050545A1 (es) | Derivados de quinazolinonas y su uso como inhibidores de b-raf | |
| AR063643A1 (es) | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas | |
| AR053683A1 (es) | Derivados de piperidina con actividad antibacteriana | |
| AR056556A1 (es) | Imidazo(1,2-a)piridina con actividad antiproliferacion celular | |
| AR056184A1 (es) | Compuestos derivados de pirazol, composicion farmaceutica en base a aquellos y su uso para la fabricacion de medicamentos | |
| AR061652A1 (es) | Derivados de pirimidina, un metodo para su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de gsk3. | |
| AR040408A1 (es) | Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| AR056210A1 (es) | 4-(3-aminopirazol)pirimidina para uso como inhibidores de tirosina-quinasa | |
| AR072045A1 (es) | Derivados heterociclicos de urea y metodos para utilizarlos | |
| AR072047A1 (es) | Compuestos heterociclicos utiles para inhibir la adn girasa | |
| AR047702A1 (es) | Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular | |
| AR041594A1 (es) | Derivados de 1,4 piperidina disustituida y su uso como inhibidores de 11-beta hidroxiesteroide dehidrogenasa tipo 1 | |
| AR046616A1 (es) | Piperidinas sustituidas utiles en el tratamiento de sindrome metabolico | |
| AR046615A1 (es) | Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos | |
| AR052170A1 (es) | Derivados de pirimidina utiles por su actividad anti-proliferacion celular | |
| AR056354A1 (es) | DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO | |
| AR064130A1 (es) | Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas. | |
| AR077971A1 (es) | Derivados heterociclicos de urea y metodos de uso de los mismos | |
| AR064521A1 (es) | Activador de glucoquinasa | |
| AR076899A1 (es) | Derivados heterociclicos de la urea, composiciones farmaceuticas y su uso en el tratamiento de infecciones bacterianas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |